Efficacy Observation Of Continued Targeted Therapy For Simple Bone Progression During Targeted Therapy For EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Objective:Exploring the Efficacy observation of continued targeted therapy for simple bone progression during targeted therapy for EGFR mutation-positive advanced non-small cell lung cancer.Methods:We retrospectively analyzed and followed up the clinical data and data of patients treated in The Second Affiliated Hospital of Nanchang University from May2020 to December 2022 for EGFR-mutation-positive advanced non-small cell lung cancer who received continued targeted therapy for bone progression alone during targeted therapy.The duration of first PD in the bone area,duration of sustained EGFR-TKI,survival after bone metastasis,and overall time of progression were investigated.Kaplan-Meier method was used to estimate the time-to-event distribution and follow-up,plot the survival curve,and analyze the prognostic factors affecting these four indicators by COX proportional hazard regression model.Results:The median time for first PD in the skeletal area was 5.2 months(95%CI:3.5-6.9),and the 6-month and 1-year survival rates were 36.4% and 26.5%,respectively.The median duration of EGFR-TKI was 9.1 months(95%CI:7.5-10.7),and the 6-month and 1-year survival rates were 66.0% and 28.9%,respectively.The median survival time after bone metastasis was 22.0 months(95%CI:16.2-27.8),and the 1-year and 2-year survival rates were 78.3% and 39.9%,respectively.The median time to overall progression was 15.8 months(95%CI:8.3-23.3),and the 1-year and2-year survival rates were 66.5% and 34.9%,respectively.Conclusion:After simple bone metastases have progressed,EGFR-TKI therapy may be considered for continuation,along with appropriate local therapy,in patients with the original area of disease progression or local progression.